{"id":2386,"date":"2025-01-10T16:42:40","date_gmt":"2025-01-10T13:42:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2386"},"modified":"2025-11-03T20:30:56","modified_gmt":"2025-11-03T17:30:56","slug":"plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics\/","title":{"rendered":"Dyne Therapeutics, DM1&#039;de DYNE-101 ve DMD&#039;de DYNE-251 i\u00e7in planlar\u0131 duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Dyne Therapeutics, 10 Ocak 2025&#039;te d\u00fczenledi\u011fi bir yat\u0131r\u0131mc\u0131 etkinli\u011finde DYNE-101 ve DYNE-251 terapileri i\u00e7in olumlu klinik veriler duyurdu. Miyotonik distrofi tip 1 (DM1) i\u00e7in DYNE-101, \u00f6nemli ekleme d\u00fczeltmesi ve i\u015flevsel iyile\u015ftirmeler g\u00f6sterdi ve bu durum Dyne&#039;\u0131, 6,8 mg\/kg Q8W&#039;lik bir kay\u0131t dozu ve 2026&#039;n\u0131n ilk yar\u0131s\u0131nda olas\u0131 bir ABD H\u0131zland\u0131r\u0131lm\u0131\u015f Onay ba\u015fvurusu ile ACHIEVE denemesinin k\u00fcresel bir Kay\u0131t Geni\u015fletme Kohortu planlamaya y\u00f6neltti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu arada, Duchenne kas distrofisini (DMD) hedefleyen DYNE-251, distrofini bir vekil u\u00e7 nokta olarak temel alarak ABD H\u0131zland\u0131r\u0131lm\u0131\u015f Onay\u0131&#039;n\u0131 da takip ediyor ve 2025&#039;in sonlar\u0131nda verilerin 2026&#039;n\u0131n ba\u015flar\u0131nda bir ba\u015fvuruyu desteklemesi bekleniyor. Her iki program da bu genetik hastal\u0131klar i\u00e7in tedavi paradigmalar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrmede umut vadediyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg\/kg Q8W [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[118,66,143,144,145],"class_list":["post-2386","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duchenne","tag-duchenne-muscular-dystrophy","tag-dyne","tag-dyne-101","tag-dyne-251"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2386"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2388"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}